The evolution of alternative splicing in glioblastoma under therapy

Lin Wang,Karin Shamardani,Husam Babikir,Francisca Catalan,Takahide Nejo,Susan Chang,Joanna J. Phillips,Hideho Okada,Aaron A. Diaz

DOI: https://doi.org/10.1186/s13059-021-02259-5

IF: 17.906

2021-01-26

Genome Biology

Abstract:Abstract Background Alternative splicing is a rich source of tumor-specific neoantigen targets for immunotherapy. This holds promise for glioblastomas (GBMs), the most common primary tumors of the adult brain, which are resistant to standard-of-care therapy. Although most clinical trials enroll patients at recurrence, most preclinical studies have been done with specimens from primary disease. There are limited expression data from GBMs at recurrence and surprisingly little is known about the evolution of splicing patterns under therapy. Result We profile 37 primary-recurrent paired human GBM specimens via RNA sequencing. We describe the landscape of alternative splicing in GBM at recurrence and contrast that to primary and non-malignant brain-tissue specimens. By screening single-cell atlases, we identify cell-type-specific splicing patterns and novel splicing events in cell-surface proteins that are suitable targets for engineered T cell therapies. We identify recurrent-specific isoforms of mitogen-activated kinase pathway genes that enhance invasiveness and are preferentially expressed by stem-like cells. Conclusion These studies shed light on gene expression in recurrent GBM and identify novel targets for therapeutic development.

genetics & heredity,biotechnology & applied microbiology